

* 盧勝男醫師

所有發表期刊論文

1. Tsai MC, Chen CH, Hu TH, Lu SN, Lee CM, Wang JH, Hung CH*. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. *J Formos Med Assoc.* 2017 July; 116(7):512-521. (SCI)
2. Hung CH*, Kee KM, Chen CH, Tseng PL, Tsai MC, Chen CH, Wang JH, Chang KC, Kuo YH, Yen YH, Hu TH, Lu SN. A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation. *Clin Transl Gastroenterol.* 2017 Jun 29;8(6):e104. (SCI)
3. Wu CH, Hsu TY, Kung FT, ChangChien CC, Tsai CC, Lu SN*. Changes in the Prevalence of HBsAg and HBeAg: a Study of 8696 Parturients in a Well Vaccinated Area. *Sci Rep.* 2017 Apr 27;7(1):1212.(SCI)(2015 SCI; IF= 5.228, MULTIDISCIPLINARY SCIENCES 7/63=11.11%)
4. Kee KM, Lu SN*. Diagnostic efficacy of ultrasound in hepatocellular carcinoma diagnosis. *Expert Rev Gastroenterol Hepatol.* 2017 Apr;11(4):277-279. (Editorial)
5. Chien TL, Wang JH, Kee KM, Chen CH, Hung CH, Lu SN*. Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function. *PLoS One.* 2016 Dec 9;11(12):e0166543. (SCI)
6. Wang JH, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, Lee CM, Lu SN*. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. *Liver Int.* 2016 Dec;36(12):1793-1799.(SCI)以肝纖維化測量為基礎的分數預測慢性 C 型肝炎病人治療成功後的肝癌發生風險
7. Kee KM, Wang JH, Wang CC, Cheng YF, Lu SN*. Hepatocellular Carcinoma associated with Extra-hepatic Primary Malignancy: its Secular change, Clinical Manifestations and Survival. *Sci Rep.* 2016 Jul 22;6:30156. (SCI)
8. Yap YS, Chuang KW, Chiang CJ, Chuang HY, Lu SN*. Geographic Variation of Chronic Kidney Disease Prevalence: Correlation with the Incidence of Renal Cell Carcinoma or Urothelial Carcinoma? *Biomed Res Int.* 2015;2015:427084. (SCI)
9. Yeh JH, Hung CH, Wang JH, Kuo YH, Tai WC, Lu SN*. Hepatocellular carcinoma detected by regular surveillance: Does timely confirmation of diagnosis matter? *Dig Liver Dis.* 2016 June;48(6):661-666. (SCI)
10. Kuo YH, Tsai MC, Kee KM, Chang KC, Wang JH, Lin CY, Lin SC, Lu SN*. Associated Factors for Metabolic Syndrome in the Older Adults with Chronic Virus Hepatitis in the Community. *PLoS One.* 2016 May 13;11(5):e0155544.

(SCI)社區老年慢性肝炎者有代謝症候群的相關因子

11. Wang JH(co-first), Chen TY(co-first), Ou HY, Wang CC, Liu YW, Hung CH, Chen CH, Kuo CH, Hu TH, Cheng YF, Lu SN*. Clinical Impact of Gadoteric Acid-Enhanced Magnetic Resonance Imaging on Hepatoma Management: A Prospective Study. *Dig Dis Sci*. 2016 Apr;61(4):1197-205. (SCI)Primovist 核磁共振檢查影響肝癌臨床處理的前瞻研究
12. Yeh JH, Hung CH, Wang JH, Chen CH, Kee KM, Kuo CM, Yen YH, Cheng YF, Chen YY, Hsu HC, Lu SN*. Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. *PLoS One*. 2015 Dec 14;10(12):e0144893. (SCI)
13. Kuo YH, Lu SN*. Role of serum quantitative hepatitis B surface antigen (HBsAg) in HBsAg carriers in a follow-up community study. *Kaohsiung J Med Sci*. 2015 July; 31(7):386-387. (SCI)(letter)
14. Kuo YH, Chen PF, Wang JH, Chang KC, Kee KM, Tsai MC, Lin CY, Lin SC, Tsai LS, Chen SC, Lu SN*. Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care. *PLoS One*. 2015 May 13;10(5):e0126031. (SCI)
15. Wang JH, Kee KM, Lin CY, Hung CH, Chen CH, Lee CM, Lu SN*. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2015 Feb;30(2):358-63. (SCI)
16. Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Lu SN*. Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: A follow-up study of an elderly cohort. *Kaohsiung J Med Sci*. 2015 Feb; 31(2): 102–107. (SCI)
17. Lee MH*, Lu SN*, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L'Italien G, Chen CJ*; R.E.V.E.A.L.-HCV Study Group. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. *PLoS One*. 2014 May 6;9(5):e94760. (SCI)
18. Kee KM, Hung CH, Wang JH, Lu SN*. Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib. *OncoTargets and Therapy*. 2014 May;7:829-834. (SCI)
19. Kee KM, Wang JH, Lin CY, Wang CC, Cheng YF, Lu SN*. Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center. *Dig Dis Sci*. 2013 Sep;58(9):2721-8.

(SCI)

20. Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Lu SN. Improvement of Thrombocytopenia in Hepatitis C-Related Advanced Fibrosis Patients After Sustained Virological Response. *Dig Dis Sci*. 2013 Feb;58(2):556-61. (SCI)
21. Chen CT, Chen JY, Wang JH, Chang KC, Tseng PL, Kee KM, Chen PF, Tsai LS, Chen SC, Lin SC, Lu SN*. Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan. *Kaohsiung J Med Sci*. 2013 Aug;29(8):451-9. (SCI)
22. Tseng PL, Wang JH, Hung CH, Tung HD, Chen TM, Huang WS, Liu SL, Hu TH, Lee CM, Lu SN*. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. *Kaohsiung J Med Sci*. 2013 Jul;29(7):385-95. (SCI)
23. Wang JH, Lu SN*. Response to Giannini et al. *Am J Gastroenterol*. 2013 Jul;108(7):1175. (SCI)
24. Chen CH, Lee CM, Wang JH, Hu TH, Hung CH, Changchien CS, Lu SN*. Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. *Hepatol Int*. 2013 June;7(2):477-488. (SCI)
25. Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH, Tai WC, Tsai LS, Chen SC, Lin SC, Lu SN*. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. *Am J Gastroenterol*. 2013 Mar;108(3):416-24. (SCI)
26. Wang JH, Wang CC(co-first), Hung CH, Chen CL, Lu SN*. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. *J Hepatol*. 2012 Feb;56(2):412-8. (SCI)
27. Liu JL, Chen JY, Chen CT, Wang JH, Lin CY, Chen PF, Hung CH, Kee KM, Lee CM, Tsai LS, Chen SC, Lin SC, Lu SN*. Community-based cross-sectional study: the association of lipids with hepatitis C seropositivity and diabetes mellitus. *J Gastroenterol Hepatol*. 2012 Nov;27(11):1688-94. (SCI)
28. Lu SN. Cross-stage and combination treatment for Barcelona Clinic of Liver Cancer stage B (intermediate stage) hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2012 Jun;27(6):991-3. (SCI)
29. Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Chen CH, Lu SN*. Is hepatitis C virus core antigen an adequate marker for community screening?

- J Clin Microbiol. 2012 Jun;50(6):1989-93. (SCI)
30. Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Chang KC, Tseng PL, Yen YH, Lin CY, Lu SN*. Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study. J Gastroenterol Hepatol. 2012 Jun;27(6):1106-11. (SCI)
 31. Kee KM, Lu SN*. Hospital- and community-based screenings for hepatocellular carcinoma in Taiwan. Oncology. 2011;81 Suppl 1:36-40. (SCI)
 32. Tsai PS, Chang CJ, Chen KT, Chang KC, Hung SF, Wang JH, Hung CH, Chen CH, Tseng PL, Kee KM, Yen YH, Tsai CC, Lu SN*. Acquisition and disappearance of HBsAg and anti-HCV in an aged population: a follow-up study in an endemic township. Liver Int. 2011 Aug;31(7):971-9. (SCI)
 33. Chen CT, Kuo YH, Huang CF, Huang CF, Lu SN*. Treatment Effects of Standard of Care for Chronic Hepatitis C in Real World: A Personal Experience of A Hepatologist in A Medical Center in Southern Taiwan. J Intern Med Taiwan 2011 June; 22(3): 192-198. 內科學誌慢性 C 型肝炎標準照顧在臨床上的療效：南台灣醫學中心某醫師的經驗
 34. Hung CH, Lee CM, Lu SN*. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther. 2011 May;9(5):525-33. Review. (SCI)
 35. Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN*. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients. J Gastroenterol Hepatol. 2011 Mar;26(3):461-8. (SCI)
 36. Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN*. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer. 2011 May 15;128(10):2344-52. (SCI)
 37. Huang YC, Huang CF, Chang KC, Hung SF, Wang JH, Hung CH, Chen CH, Tseng PL, Kee KM, Yen YH, Tsai PS, Tsai CC, Lu SN*. Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area. J Gastroenterol Hepatol. 2011 Jan;26(1):129-34. (SCI)
 38. Wang JH, Tung HD, Chen TY, Hung CH, Chen CH, Changchien CS, Hu TH, Lee CM, Lu SN*. Radiofrequency ablation of small hepatocellular carcinoma with intravenous pegylated liposomal doxorubicin. Hepatol Int. 2011 Mar; 5(1): 567-574. (SCI)
 39. Chen JY, Wang JH, Lin CY, Chen PF, Tseng PL, Chen CH, Chang KC, Tsai LS, Chen SC, Lu SN*. Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both hepatitis B

- and C strains independently. *J Gastroenterol Hepatol*. 2010 Nov;25(11):1763-8. (SCI)
40. Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen PF, Tsai LS, Lu SN*. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. *J Gastroenterol Hepatol*. 2010 Aug;25(8):1426-34. (SCI)
 41. Kee KM, Hung CM, Wang JH, Hung CH, Chen PF, Lin KS, Lu SN*. Low accuracy of the national reporting system of acute hepatitis C infection in Taiwan, 1995-2004. *J Gastroenterol Hepatol*. 2010 Jul;25(7):1289-94. (SCI)
 42. Wang JH, Changchien CS, Hung CH, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, Lu SN*. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. *J Gastroenterol Hepatol*. 2010 May;25(5):964-9. (SCI)
 43. Chang KC, Tsai PS, Hsu MC, Hung SF, Tsai CC, Lu SN*. Chronic hepatitis C increased the mortality rates of patients with hepatocellular carcinoma and diabetes mellitus in a triple hepatitis virus endemic community. *J Gastroenterol*. 2010 Jun;45(6):636-45. (SCI)
 44. Tung HD, Wang JH, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, Lu SN*. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. *Am J Gastroenterol*. 2010 Mar;105(3):624-31. (SCI)Erratum in: *Am J Gastroenterol*. 2010 Jun;105(6):1455.
 45. Tsai MC, Wang JH, Hung CH, Kee KM, Yen YH, Lee CM, Hu TH, Chen CH, Lu SN*. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. *J Gastroenterol Hepatol*. 2010 Mar;25(3):605-12. (SCI)
 46. Su WW, Chen CH, Lin HH, Yang SS, Chang TT, Cheng KS, Wu JC, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Lu SN*. Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. *Hepatol Int*. 2009 Dec;3(4):537-43. (SCI)
 47. Chiang JC, Lin CY, Wang JH, Kee KM, Chen PF, Chen YD, Tsai LS, Chen TH, Lu SN*. Identifying hepatitis C virus: endemic areas and estimating the viral antibody prevalence based on the prevalence of ALT elevation. *Trans R Soc Trop Med Hyg*. 2009 Sep;103(9):917-23. (SCI)
 48. Lin CY, Kee KM(co-first), Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH,

- Cheng YF, Hsu HC, Wang CC, Chen TY, Lu SN*. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. *Liver Int.* 2009 Jan;29(1):74-81. (SCI)
49. Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, Hu TH, Lee CM, Lin CY, Wang CC, Chen TY, Huang YJ, Lu SN*. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. *Dig Liver Dis.* 2009 Jun;41(6):431-41. (SCI)
50. Wang JH, Changchien CS, Hung CH, Eng HL, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, Lu SN*. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. *J Gastroenterol.* 2009;44(5):439-46. (SCI)
51. Huang YJ, Hsu HC, Wang CY, Wang CJ, Chen HC, Huang EY, Fang FM, Lu SN*. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2009 Mar 15;73(4):1155-63. (SCI)
52. Kao JT, Wang JH, Hung CH, Yen YH, Hung SF, Hu TH, Lee CM, Lu SN*. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. *Vaccine.* 2009 Mar 13;27(12):1858-62. (SCI)
53. Kao JT, Wang JH, Hung CH, Hu TH, Lee CM, Hung SF, Lu SN*. Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C-endemic area: cross-sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination. *Liver Int.* 2008 Nov;28(9):1298-304. (SCI)
54. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen TY, Huang YJ, Lu SN*. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. *Eur J Cancer.* 2008 May;44(7):1000-6. (SCI)
55. Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY, Lu SN*. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. *J Gastroenterol.* 2008;43(2):159-70. (SCI)
56. Lu SN, Yen YH, Lin CY, Kee KM, Wang JH, Changchien CS*. Clinical Staging of Hepatocellular Carcinoma. *Journal of The Chinese Oncology Society* 2008 Oct. 24(5):295-303. 中華民國癌症醫學會雜誌
57. Lu SN*, Wang JH, Chen PF, Tung HD, Tseng PL, Hung CH, Kee KM, Chen CH,

Chang KC, Lee CM, Changchien CS, Chen YD, Tsai LS, Chen TH.
Community-based mass ultrasonographic screening of hepatocellular
carcinoma among thrombocytopenic adults. *Cancer Epidemiol Biomarkers
Prev.* 2008 Jul;17(7):1813-21. (SCI)